Cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder
Robert H Pietrzak1, Catherine M Mollica, Paul Maruff
1Department of Psychology, Clinical Division, University of Connecticut, 406 Babbidge Road, Unit 1020, Storrs, CT 06269-1020, USA.
Insights
Methylphenidate medication improved cognitive functions in children with attention-deficit/hyperactivity disorder (ADHD). Studies show benefits in attention, planning, and impulse control, though results vary.
Area of Science:
- Neuroscience
- Child Psychology
- Pharmacology
Background:
- Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder.
- Methylphenidate is a widely prescribed stimulant medication for ADHD.
- Previous reviews exist, but a comprehensive update on cognitive effects is needed.
Purpose of the Study:
- To systematically review and synthesize findings on the cognitive effects of immediate-release methylphenidate in children with ADHD.
- To determine the types and magnitude of cognitive improvements associated with methylphenidate treatment.
- To identify potential reasons for variability in study outcomes.
Main Methods:
- Conducted a literature search for placebo-controlled studies on methylphenidate's cognitive effects in children with ADHD.
- Included 40 relevant studies published since 1993.
- Analyzed reported improvements in various cognitive domains.
Main Results:
- 63.5% of studies reported overall cognitive improvement with methylphenidate.
- Significant improvements were noted in saccadic eye movement (83.3%), planning/cognitive flexibility (71.4%), attention/vigilance (70.6%), and inhibitory control (69.7%).
- Memory and working memory/divided attention tasks showed improvement in 58.3% and 50% of studies, respectively.
Conclusions:
- Immediate-release methylphenidate demonstrates a positive impact on several cognitive functions in children with ADHD.
- Variability in findings may stem from medication's differential brain effects, individual responses, and methodological factors.
- Further research is needed to understand and mitigate response variability.
Abstract:
A growing body of literature has examined the cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD). However, a clear understanding of the types and magnitude of such effects are difficult to discern from such a large and varied collection of published reports. This review evaluated a total of 40 relevant placebo-controlled studies published since Rapport and Kelly's [1993. Psychostimulant effects on learning and cognitive function. In: Matson, J.L. (Ed.), Handbook of Hyperactivity in Children. Allyn & Bacon, Boston, pp. 97-136] original review of cognitive effects of methylphenidate in children with ADHD. Of these published studies, 63.5% identified some improvement in cognitive function following methylphenidate treatment. Methylphenidate improved performance on saccadic eye movement, planning/cognitive flexibility, attention/vigilance, and inhibitory control tasks in 83.3%, 71.4%, 70.6%, and 69.7% of studies, respectively. A total 58.3% and 50% of studies that evaluated the effect of methylphenidate on tasks of memory and working memory/divided attention, respectively, noted improvement. Variability of findings across studies may be explained by differential effects of methylphenidate on brain function, intra- and inter-individual variability in medication response, methodological limitations, and problems associated with repeated neuropsychological assessment and metric properties of commonly utilised neuropsychological instruments.
More Related Videos
Related Concept Videos
01:30Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
01:28Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
01:25Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:30Information Processing Approach